REG - C4X Discovery - Posting of 2023 Annual Report and Notice of AGM

C4X Discovery HoldingsAnnouncement

18/12/2023 15:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231218:nRSR1947Xa&default-theme=true

RNS Number : 1947X  C4X Discovery Holdings PLC  18 December 2023

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

Posting of 2023 Annual Report and Notice of AGM

 

18 December 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, announces that it has today published and posted to
shareholders the Annual Report and Accounts for the year ended 31 July 2023
and Notice of the Annual General Meeting ("AGM") which will be held at Panmure
Gordon, 40 Gracechurch Street, EC3V 0BT, on 23 January 2024 at 11.30 a.m.
(GMT).

The Annual Report and Accounts and Notice of AGM are also available to view
on, and download from, the Company's website at www.c4xdiscovery.com
(http://www.c4xdiscovery.com)

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company, combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world‑leading medicines.  We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced candidate
molecule design and patient stratification capabilities, generating small
molecule drug candidates across multiple disease areas focused on
immuno-inflammation.  Our commercially attractive portfolio ranges from
early-stage target opportunities to late-stage Drug Discovery programmes and
we have three commercially partnered programmes with one candidate in clinical
development.

 

For more information visit us at www.c4xdiscovery.com
(http://www.c4xdiscovery.com) or follow us on twitter @C4XDiscovery.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOATPBATMTJBBMJ